Journal of Stem cell Research and Therapy

Vitaly Viktorovich Kadyshev is an outstanding physician-scientist whose professional work has significantly influenced the development of domestic ophthalmology and medical genetics, refining approaches to the diagnosis and treatment of rare inherited eye diseases. After graduating with a medical degree from the Russian State Medical University in 2006, he completed his clinical residency at the Moscow Helmholtz Research Institute of Eye Diseases (2006–2008) and his postgraduate studies at the Research Centre for Medical Genetics (2008–2011). He defended his Candidate of Sciences dissertation in 2011 and his Doctor of Sciences dissertation in 2023, establishing himself as a recognized expert at the intersection of ophthalmology and genetics. Since 2016, he has held the highest qualification category in the specialty of "Ophthalmology." Throughout his years of clinical practice, Vitaly Viktorovich has conducted over 27,000 consultations for patients with severe rare ophthalmic pathologies, with a particular focus on rare and hereditary diseases. He developed a unique comprehensive examination system that significantly reduces diagnostic time and improves its accuracy. His contribution to advancing systems for timely therapeutic and preventive care, actively integrating the latest achievements in medical genetics, is especially noteworthy. The unique algorithms he developed for the early diagnosis of inherited ophthalmopathies—utilizing NGS sequencing and MLPA analysis in combination with innovative ophthalmic technologies (OCT angiography, adaptive optics)—have achieved unprecedented diagnostic accuracy (98.3%), even for the rarest forms of pathology. The patient monitoring system he created for individuals with hereditary eye diseases ensures treatment initiation at pre-clinical stages, which has prevented the development of irreversible changes in 68% of patients and reduced vision-related disability by 42% within the observed cohort. He also implemented a telemedicine consultation system in the field of ophthalmic genetics. He participated in organizing 18 unique specialized genetic-epidemiological expeditions to remote and new regions of Russia, providing care to patients and collecting scientific data on hereditary eye diseases. He created Russia's first nationwide database of patients with aniridia, albinism, and hereditary retinal pathology, encompassing 87 federal subjects. Vitaly Viktorovich's scientific output includes more 130 publications (more than 35 in international journals), 10 patents, 4 clinical guidelines, and 3 methodological manuals. The diagnostic protocols and treatment methods he developed have been implemented in 12 federal and 23 regional clinics, as well as in 3 partner medical institutions abroad, generating significant economic benefits. His mentoring and pedagogical activities are of particular importance. He has developed 4 educational courses, trained over 30 unique specialists for the regions, supervised 2 Candidates of Sciences, and founded a school of ophthalmic genetics. Annually, he conducts 12-15 master classes for physicians, residents, and medical students and participates in organizing all-Russian educational projects for doctors. His trainees now work successfully in leading medical centers across the country. His expert activities include membership in Russian and international professional ophthalmological and genetic societies, scientific editorship of medical journals, and participation in international professional associations. The conferment of the honorary title "Honored Doctor of the Russian Federation" upon Vitaly Viktorovich Kadyshev is a well-deserved recognition of his contribution to the development of Russian medicine and an important step in enhancing the prestige of Russian medical science, confirming that the country is home to specialists of world-class caliber. His medical practice serves as a model of dedicated service to medical science and practice, combining scientific boldness, clinical mastery, and organizational talent.

• Ophthalmogenetics
• Genetic Epidemiology
• Molecular Diagnostics
• Genomic Medicine
• Clinical Ophthalmology

• National Coordinator for Hereditary Eye Diseases in the Russian Federation.
• Expert for the "Krug Dobra" (Circle of Kind) Foundation.
• Expert of the Russian Academy of Sciences (RAS).
• Head of the Scientific and Clinical Centre for Ophthalmology (2021–2024).

Research Focus Areas:

• Ophthalmogenetics and hereditary eye diseases.
• Genetic epidemiology and molecular diagnostics.
• Public health and healthcare management.
• Development of genetic counseling systems in ophthalmology.
• Integration of genomics into clinical ophthalmic practice.

1. Dianat-Moghadam H, Heidarifard M, Jahanban-Esfahlan R, Panahi Y, et al. (2018). Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. Journal of Controlled Release, 288, 62–83.
2. Dianat-Moghadam H, Azizi M, Eslami-S Z, Cortés-Hernández LE, et al. (2020). The role of circulating tumor cells in the metastatic cascade: biology, technical challenges, and clinical relevance. Cancers, 12(4), 867.
3. Dianat-Moghadam H, Mahari A, Heidarifard M, Parnianfard N, et al. (2021). NK cells-directed therapies target circulating tumor cells and metastasis. Cancer Letters, 497, 41–53.
4. Keshavarz M, Nejad ASM, Esghaei M, Bokharaei-Salim F, Dianat-Moghadam H, et al. (2020). Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi Journal of Biological Sciences, 27(1), 47–52.
5. Dianat-Moghadam H, Mahari A, Salahlou R, Khalili M, Azizi M, et al. (2022). Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy. Stem Cell Research & Therapy, 13(1), 1–12.
6. Dianat-Moghadam H, Heidarifard M, Mahari A, Shahgolzari M, et al. (2020). TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacological Research, 104716.
7. Dianat-Moghadam H, Rokni M, Marofi F, Panahi Y, Yousefi M. (2019). Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells. Journal of Cellular Physiology, 234(1), 259–273.
8. Keshavarz M, Dianat-Moghadam H, Sofiani VH, Karimzadeh M, Zargar M, et al. (2018). miRNA-based strategy for modulation of influenza A virus infection. Epigenomics, 10(6), 829–844.
9. Ayoubi-Joshaghani MH, Dianat-Moghadam H, Seidi K, et al. (2020). Cell-free protein synthesis: The transition from batch reactions to minimal cells and microfluidic devices. Biotechnology and Bioengineering, 117(4), 1204–1229.
10. Sadeghzadeh H, Dianat-Moghadam H, Bakhshayesh D, Rahmani A, et al. (2023). A review on the effect of nanocomposite scaffolds reinforced with magnetic nanoparticles in osteogenesis and healing of bone injuries. Stem Cell Research & Therapy, 14(1), 1–17.